- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07637331
The Effect of Respiratory Muscle Training on Cognitive Performance
June 24, 2026 updated by: Blair D. Johnson, PhD, Indiana University
Determine if exercise training for the respiratory muscles improves cognitive performance during periods when breathing against a resistance.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Blair Johnson
- Phone Number: 812-855-8699
- Email: bj33@iu.edu
Study Locations
-
-
Indiana
-
Bloomington, Indiana, United States, 47405
- Recruiting
- Indiana University
-
Contact:
- Blair Johnson, PhD
- Phone Number: 812-855-8699
- Email: bj33@iu.edu
-
Principal Investigator:
- Blair Johnson, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-40 years old
- Body mass index <30 kg/m2
- Naïve to IMT
- >75% of predicted forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) (FEV1/FVC)
- Access to smart phone or tablet with internet
Exclusion Criteria:
Diagnosed:
- Cardiovascular disease
- Respiratory disease (including asthma)
- Metabolic disease
- Currently pregnant
- Unable to adhere to the IMT protocol
- Answering 'yes' to any of the questions on page one of the PAR-Q+
- Abnormal cognition assessed via the Montreal Cognitive Assessment (score of 25 or less)
- Self-reported color blindness
- Significant acute or chronic medical, neurologic, or illness in the participant that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability of the participant to complete the study, and/or compromise the objectives of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active IMT
Inspiratory muscle training
|
8 weeks of active or sham inspiratory muscle training
|
|
Sham Comparator: Sham IMT
Sham inspiratory muscle training
|
8 weeks of active or sham inspiratory muscle training
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaphragm thickness
Time Frame: Baseline and after 8 weeks of training
|
ultrasound measurements of diaphragm thickness
|
Baseline and after 8 weeks of training
|
|
Cognitive performance
Time Frame: Baseline and after 8 weeks of training
|
CAAPES performance with the higher percentage correct corresponding to a better performance.
|
Baseline and after 8 weeks of training
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dyspnea
Time Frame: Baseline and after 8 weeks of training
|
Measure of breathing discomfort and pleasantness using a visual analog scale, the higher the value the more discomfort and unpleasant the subject's breathing is.
|
Baseline and after 8 weeks of training
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Blair Johnson, PhD, Indiana University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2026
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
April 1, 2027
Study Registration Dates
First Submitted
June 1, 2026
First Submitted That Met QC Criteria
June 4, 2026
First Posted (Actual)
June 9, 2026
Study Record Updates
Last Update Posted (Actual)
June 26, 2026
Last Update Submitted That Met QC Criteria
June 24, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 28083
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.